Overview


According to FutureWise analysis the market for mild cognitive impairment (mci) treatment in 2023 is US$ 0.08 billion, and is expected to reach US$ 0.17 billion by 2031 at a CAGR of 8.92%.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Mild Cognitive Impairment (MCI) Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Mild Cognitive Impairment (MCI) Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Eisai Co., Ltd.
  • Novartis AG
  • Cipla Inc.
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Dr. Reddy’s Laboratories Ltd.
  • Zydus Cadila
  • LUPIN
  • Torrent Pharmaceuticals Ltd.
  • Jubilant Life Sciences Ltd.
  • Alembic Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals LLC.
  • Johnson and Johnson Services, Inc.
  • Hikma Pharmaceuticals PLC.
  • Allergan
  • Lannett

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Class

  • MAO Inhibitors
  • Glutamate Inhibitors
  • Cholinesterase Inhibitors
  • Others

By Therapy Type

  • Cognitive Stimulation Therapy
  • Cognitive Behavioral Therapy (CBT)

By Route of Administration

  • Oral
  • Parenteral

By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Mild Cognitive Impairment (MCI) Treatment Market By Drug Class, By Therapy Type, By Route of Administration, By End Users, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Mild Cognitive Impairment (MCI) Treatment Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Mild Cognitive Impairment (MCI) Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Mild Cognitive Impairment (MCI) Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Mild Cognitive Impairment (MCI) Treatment Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. MAO Inhibitors
        2. Glutamate Inhibitors
        3. Cholinesterase Inhibitors
        4. Others

  • 8.   Mild Cognitive Impairment (MCI) Treatment Market, By Therapy Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Cognitive Stimulation Therapy
        2. Cognitive Behavioral Therapy (CBT)

  • 9.   Mild Cognitive Impairment (MCI) Treatment Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Oral
        2. Parenteral

  • 10.   Mild Cognitive Impairment (MCI) Treatment Market, By End Users Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others

  • 11.   Mild Cognitive Impairment (MCI) Treatment Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospital Pharmacies
        2. Online Pharmacies
        3. Retail Pharmacies

  • 12.   North America Mild Cognitive Impairment (MCI) Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Mild Cognitive Impairment (MCI) Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe Mild Cognitive Impairment (MCI) Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific Mild Cognitive Impairment (MCI) Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •       1. Eisai Co., Ltd.
               1.1. Company Overview
               1.2. Product Portfolio
               1.3. SWOT Analysis
               1.4. Financial Overview
               1.5. Strategic Overview
            2. Novartis AG
               2.1. Company Overview
               2.2. Product Portfolio
               2.3. SWOT Analysis
               2.4. Financial Overview
               2.5. Strategic Overview
           3. Cipla Inc.
               3.1. Company Overview
               3.2. Product Portfolio
               3.3. SWOT Analysis
               3.4. Financial Overview
               3.5. Strategic Overview
            4. Aurobindo Pharma
               4.1. Company Overview
               4.2. Product Portfolio
               4.3. SWOT Analysis
               4.4. Financial Overview
               4.5. Strategic Overview
           5. Sun Pharmaceutical Industries Ltd.
               5.1. Company Overview
               5.2. Product Portfolio
               5.3. SWOT Analysis
               5.4. Financial Overview
               5.5. Strategic Overview          
            6. Mylan N.V.
               6.1. Company Overview
               6.2. Product Portfolio
               6.3. SWOT Analysis
               6.4. Financial Overview
               6.5. Strategic Overview
            7. Dr. Reddy’s Laboratories Ltd.
               7.1. Company Overview
               7.2. Product Portfolio
               7.3. SWOT Analysis
               7.4. Financial Overview
               7.5. Strategic Overview
            8. Zydus Cadila
               8.1. Company Overview
               8.2. Product Portfolio
               8.3. SWOT Analysis
               8.4. Financial Overview
               8.5. Strategic Overview
            9. LUPIN
               9.1. Company Overview
               9.2. Product Portfolio
               9.3. SWOT Analysis
               9.4. Financial Overview
               9.5. Strategic Overview          
           10. Torrent Pharmaceuticals Ltd.
               10.1. Company Overview
               10.2. Product Portfolio
               10.3. SWOT Analysis
               10.4. Financial Overview
               10.5. Strategic Overview
            11. Jubilant Life Sciences Ltd.
               11.1. Company Overview
               11.2. Product Portfolio
               11.3. SWOT Analysis
               11.4. Financial Overview
               11.5. Strategic Overview
           12. Alembic Pharmaceuticals Limited
               12.1. Company Overview
               12.2. Product Portfolio
               12.3. SWOT Analysis
               12.4. Financial Overview
               12.5. Strategic Overview
           13. Teva Pharmaceutical Industries Ltd.
               13.1. Company Overview
               13.2. Product Portfolio
               13.3. SWOT Analysis
               13.4. Financial Overview
               13.5. Strategic Overview
           14. Amneal Pharmaceuticals LLC.
               14.1. Company Overview
               14.2. Product Portfolio
               14.3. SWOT Analysis
               14.4. Financial Overview
               14.5. Strategic Overview
           15. Johnson & Johnson Services, Inc.
               15.1. Company Overview
               15.2. Product Portfolio
               15.3. SWOT Analysis
               15.4. Financial Overview
               15.5. Strategic Overview
           16. Hikma Pharmaceuticals PLC.
               16.1. Company Overview
               16.2. Product Portfolio
               16.3. SWOT Analysis
               16.4. Financial Overview
               16.5. Strategic Overview
           17. Allergan
               17.1. Company Overview
               17.2. Product Portfolio
               17.3. SWOT Analysis
               17.4. Financial Overview
               17.5. Strategic Overview
           18. Lannett
               18.1. Company Overview
               18.2. Product Portfolio
               18.3. SWOT Analysis
               18.4. Financial Overview
               18.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 20.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11